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paranasal sinus adjacent to the floor of the anterior or middle
cranial fossa (shared bony wall fracture) was demonstrated in
every case. Of the 30 patients, 2 refused surgery. In the other 28
patients surgical exploration was performed and the site of the
fracture corresponded to a site of dural tear in every case. The
image published in Dr Ouma’s article is similar to a number of
the images obtained in our series. The longest interval from the
time of head injury to presentation with non-meningococcal
meningitis in our series was 13 years. Our article was one of
the first publications to document the value of direct coronal
CT scanning in this setting.
In light of the current HIV/AIDS epidemic, patients with
opportunistic intracranial infection would have to be excluded;
otherwise it is my belief that every patient who presents with
non-meningococcal meningitis should be investigated for a
possible shared bony wall fracture by undergoing a direct
coronal CT scan of the floor of the anterior and middle cranial
fossae.
Don Emby
Western Deep Levels Hospital
Western Levels
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Need and opportunities for
training health professionals in
medical genetics
To the Editor: Medical genetics is a subspecialty registrable
with the Health Professions Council of South Africa (HPCSA).
Subspecialty training in medical genetics can be undertaken in
academic centres registered with the HPCSA.
Medical genetics has played an increasing role in health care
over the last half century and the need for medical genetic
services in many developing countries including South Africa
has become apparent in the last decade. Serious birth defects
and genetic disorders comprise a wide-ranging and complex
group of conditions affecting 50 - 80 per 1 000 children in this
country and they contribute significantly to infant mortality
and morbidity. The role of genetics in medicine is set to
increase as the impact of the Human Genome Project and
future developments are brought to bear on the care and
prevention of the chronic common disorders of later life such
as cancer, hypertension, stroke, asthma and mental disorders.
Currently, South Africa boasts 13 registrable clinical
geneticists and fewer genetic counsellors. These personnel are
far too few to bring a reasonable service to the population of
this country. Currently, three departments of human genetics in
South Africa, at the Universities of Cape Town, Free State and
the Witwatersrand, are registered with the HPCSAto provide
sub-specialty training for clinicians in medical genetics.
Unfortunately, because of financial constraints and competing
priorities, posts available to undertake such training are
limited.
The Department of Human Genetics of the National Health
Laboratory Service (NHLS) (Central), based in Johannesburg,
has academic links to the Faculty of Health Sciences, University
of the Witwatersrand, and offers a 2-year training post in the
subspecialty of Medical Genetics for a specialist already
registered in Paediatrics, Obstetrics and Gynaecology or
Internal Medicine. The Colleges of Medicine of South Africa
examine appropriately trained persons for registration and a
Masters degree (Medicine) can be obtained concurrently
through the Faculty of Health Sciences at the University of the
Witwatersrand.
The Foundation for Alcohol Related Research (FARR) is
offering a bursary commensurate with the salary earned by a
specialist in public service to a selected person for training in
Medical Genetics. The position becomes available on 1 January
2003.
A 2-year training in Genetic Counselling (Masters in
Medicine) is also available for successful applicants
commencing 1 January 2003. This is a comprehensive course
similar to training schedules in the USA, Australia and Europe,
and is registrable in South Africa with the HPCSA.
Scholarships from the NHLS and the University of the
Witwatersrand are offered to successful applicants.
Applications for these fields of training can be made to:
Professor Denis Viljoen, National Health Laboratory Service,
PO Box 1038, Johannesburg, 2000. Tel: 011-489 9211, Fax: 011-
489 9226, Email: denis@mail.saimr.wits.ac.za
Denis Viljoen
Department of Human Genetics
National Health Laboratory Service
Johannesburg
Two mutations in the MTHFR
gene associated with mild
hyperhomocysteinaemia
To the Editor: We read with much interest the article by Scholtz
et al.1 on the interethnic differences in frequencies of the C677T
and A1298C mutations of the methylene tetrahydrofolate
reductase (MTHFR) gene. The importance of their findings
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probably extends beyond the associations with coronary artery
disease and may have significant implications for rheumatoid
arthritis (RA) patients treated with methotrexate (MTX). Low-
dose MTX (7.5 - 25 mg) benefits the majority of RApatients
and has become one of the most widely prescribed disease-
modifying antirheumatic drugs. However, toxicity is a major
concern and in some Western populations as many as 30% of
patients have to discontinue therapy because of adverse
effects.2 MTX toxicity is related to its inhibition of the
conversion of 5,10-methylene tetrahydrofolate to 5-methyl
tetrahydrofolate. As a result there is a fall in methyl group
donor levels, which in turn impedes remethylation of
homocysteine to methionine and ultimately results in
hyperhomocysteinaemia. Since the homozygote C677T
mutation of MTHFR is also associated with
hyperhomocysteinaemia, van Ede et al.2 postulated that the
C667T mutation might predispose to increased MTX toxicity.
Indeed, in a study of Dutch RApatients,3 they found that the
mutation was associated with an increased risk of
discontinuing MTX treatment because of adverse events
(relative risk (RR) = 2.01), and especially an increased risk for
elevated liver enzymes (RR = 2.38). The overall allele frequency
of the C667T mutation of 28% in the Dutch cohort is
significantly lower than the 36% in white South Africans (Yates,
corrected c2 = 11.26, p = 0.0008) and significantly higher than
the 4% in black South Africans (Yates’ corrected c2 = 19,
p = 0.0000) observed by Scholtz et al.1 A similar relationship
between this mutation and overall MTX toxicity has been
observed in a Japanese cohort of RApatients.4 In addition, the
latter study showed that patients with the A1298C mutation
required lower doses of MTX. Finally, there is mounting
evidence showing that folate supplementation in patients
treated with MTX reduces the risk of adverse effects, including
liver toxicity, but at the small expense of decreased efficacy.5
In the light of the above studies, we would expect to see
differences in MTX efficacy and toxicity in the different ethnic
groups in South Africa, and in particular an increased risk of
MTX toxicity in white RApatients. There are no published
studies in this regard, but our experience at the Arthritis Clinic
at Chris Hani Baragwanath Hospital suggests that MTX
toxicity is very rare in black South Africans. In a retrospective
longitudinal study of 200 black RApatients that we undertook
in 1997,6 of the 60 patients treated with MTX for a median
period of 20 months (interquartile intervals: 11, 32), none
discontinued the drug because of adverse effects, whereas MTX
had to be discontinued in 11 patients because of lack of efficacy.
It is therefore tempting to speculate that the lack of serious
side-effects in our patients is related, at least in part, to the
rarity of the C667T mutation in black South Africans. Clearly,
this hypothesis can only be confirmed by conducting a
prospective study to examine the relationship between the
MTHFR gene mutations and efficacy and toxicity of MTX in
the various ethnic groups in South Africa. The outcome may
have practical implications for monitoring of MTX toxicity in
RApatients locally, especially with regard to liver function
tests.
Mohammed Tikly
Nedi Zannettou
Beverly Traub
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